Xvivo Perfusion Ab · OMXSTO:XVIVO
Xvivo Perfusion Ab — Q1 2026 Earnings Presentation
24 slides from Xvivo Perfusion Ab's earnings presentation, Apr 24, 2026
Slide 1: Interim report Q1 2026
Interim report Q1 2026 Earnings call, April 24, 2026 XVIVO Perfusion AB (publ) Kim Castellano Heart transplant recipient, US
Slide 2: Today's presenters
Today’s presenters Christoffer Kristoffer Rosenblad Nordström CEO CFO 2 DOC ID: Interim report Jan-Mar 2026
Slide 3: Q1 Financials – at a glance
Q1 Financials – at a glance Organic growth, local currencies Net Sales Thoracic Net sales SEK 241 Million Net Sales SEK 160 million +27%** Gross margin 83% Sales growth Organic Abdominal Net sales growth +23%* Net Sales SEK 66 million Gross margin 54% +24% - Currency effect -13% - Total growth 10% S
Slide 4: YTD highlights
YTD highlights Alex Moroianu Heart transplant recipient, AU 4 DOC ID: Interim report Jan-Mar 2026
Slide 5: Q1 Operations - Highlights
Q1 Operations - Highlights Back-to-back record Proof-of-concept from 1st 1 2 sales quarter OPO EVLP hub model Kidney sales acceleration Last patient included in 3 - growing interest in NAM 4 CAP – rapid enrollment Record penetration for Compassionate use heart 5 heart in Australia – 6 sales in 4 EU
Slide 6: ISHLT 2026
ISHLT 2026 XVIVO highlights at the on-going ISHLT in Toronto April 22-25: Late breaking abstracts • Preliminary 12-month data from the US PRESERVE trial presented by Dr. Victor Pretorius • HOPE in direct procurement DCD – first clinical trial presented by Prof. Filip Rega Industry symposia • April 2
Slide 7: US PRESERVE trial
US PRESERVE trial Preliminary one-year follow-up data from the US PRESERVE trial for XVIVO’s heart technology presented at ISHLT - A total of 141 transplant recipients were enrolled at 14 US transplant centers. - The trial (NCT05881278) included adult recipients of hearts from donors meeting specifi
Slide 8: HOPE-at-Heart trial
HOPE-at-Heart trial Encouraging results from first clinical trial using hypothermic oxygenated perfusion (HOPE) in direct procurement DCD heart transplantation presented at ISHLT - In a single-arm, proof-of-concept trial 40 adult heart transplant recipients across four European transplant centers in
Slide 9: New publication on NIHP2019
New publication on NIHP2029 The European multicenter heart trial, NIHP2019, results have now been published in the European Heart Journal1. Recap on the results: • 76 % risk reduction in severe PGD – the leading cause of mortality after heart transplantion • The risk reduction translated into an imp
Slide 10: Regulatory update
Regulatory update 10 DOC ID: Interim report Jan-Mar 2026
Slide 11: Clinical Trial Status & Tentative Timeline
Clinical Trial Status & Tentative Timeline REVIEW & PRECLINICAL CLINICAL MARKET APPROVAL FOLLOW-UP • Patient enrolment completed May 2023 • 204 patients included across 15 centers 12-month 12-month patient Commercial launch across 8 countries patient follow-up completed pending CE-mark* • Results we
Slide 12: Update - Liver Assist in the US
Update - Liver Assist in the US Regulatory pathway update • All regulatory approvals obtained to initiate the PMA study • Trial activities temporarily paused to evaluate faster and more cost-efficient regulatory pathways • First HOPE DeNovo liver perfusion now FDA-approved • Planning for a Q-sub mee
Slide 13: Financial Performance Q1
Financial Performance Q1 13 DOC ID: Interim report Jan-Mar 2026
Slide 14: Net sales and key ratios
Net sales and key ratios Jan-Mar Jan-Mar Full Year SEK Million 2026 2025 2025 Net sales 241 219 812 Sales growth, % 10 % +18 % -1 % - Organic growth*, % +23 % +14 % +3 % - Organic growth* excluding trial revenue, % +18 % +14 % +8 % Gross profit 171 160 599 Gross margin, % 71 % 73 % 74 % EBIT (adj) 3
Slide 15: Thoracic – Q1 Highlights
Thoracic – Q1 Highlights Net sales by Net sales by Net sales by organ Net Sales region product category 160 MSEK (142) 12% 2% Organic growth 22% +27 % (16) 32% 6% Organic growth (excl. heart trial revenue) 66% +19 % (16) 88% 72% Gross margin 83 % (82) Lung Heart Americas APAC Machine perfusion Stati
Slide 16: Abdominal – Q1 Highlights
Abdominal – Q1 Highlights Net sales by Net Sales Net sales by organ region 66 MSEK (56) 13% Organic growth 24 % (28) 31% 7% Gross margin 54 % (63) 69% 80% Liver Kidney Americas APAC EMEA Liver sales Kidney sales Q1 45 MSEK (43) 20 MSEK (14) +12% +63% 16 DOC ID: Interim report Jan-Mar 2026
Slide 17: Services – Q1 Highlights
Services –Q1 Highlights Net Sales Net sales by service 2026 focus: 16 MSEK (20) • Return to growth – leveraging Organ Recovery strengthened surgical capacity, NRP Organic growth service offering and EVLP momentum 25% -10 % (-6) • Preparations for US heart launch Gross margin 18 % (38) 75% 2026 focus
Slide 18: EBITDA
EBITDA Q1 2026 EBITDA (adj), by quarter EBITDA (adj), R12 months SEKm SEKm • XVIVOs scalable business model combined with strong gross margins provides a solid 40% 250 40% foundation for increasing profitability over time 70 225 35% 35% • R12 Trend weakened in 2025 due to sales 60 56 200 183 188 dev
Slide 19: Cashflow and financial position
Cashflow and financial position Cash flow from Cashflow from Q1 Cashflow operating activities (R12) R12 investing activities • Second consecutive quarter with +182m SEKm Q1 Q1 YTD positive total cashflow 200 SEKm 2026 2025 2025 182 • Cash flow from operating 175 Total cashflow activities SEK +65 mil
Slide 20: Outlook
Outlook Alex Moroianu Heart transplant recipient, AU 20
Slide 21: XVIVO is changing the future of organ transplantation
XVIVO is changing the future of organ transplantion Focus 2026 • Drive continued EVLP adoption in the US by leveraging centralized perfusion service models • Strengthen our commercial presence related to Flowhawk and Organ recovery in the US • Further develop our European leadership in liver perfusi
Slide 22: Long term outlook
Long term outlook • The demand for transplants are x 10 of today’s supply • Sales value of machine perfusion vs cold static storage is ~x 10 • Machine perfusion and service models have proven to increase the number of organs used for transplantation • XVIVO has unique, innovative and world leading p
Slide 23: Nobody should die waiting for a new organ
Nobody should die waiting for a new organ Fredrica Höglund Liver transplant recipient, Sweden 23 DOC ID: Interim report Jan-Mar 2026
Slide 24: Financial calendar & contacts
Financial calendar & contacts Financial reports 2026 Investor Relations Interim report April – June 2026: July 14, 2026 Christoffer Rosenblad, CEO Telephone: +46 735 19 21 59 Interim report July – September 2026: October 22, 2026 E-mail: christoffer.rosenblad@xvivogroup.com Year-end report 2026: Jan